Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-09-12
2006-09-12
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S008100, C536S017200, C536S017900, C536S018100, C530S387200
Reexamination Certificate
active
07105491
ABSTRACT:
This invention provides nucleic acid sequences and characterization of the gene cluster responsible for the biosynthesis of the enediyne C-1027 (produced byStreptomyces globisporus). Methods are provided for the biosynthesis of enediynes, enediyne analogs and other biological molecules. This invention also provides enediyne and enediyne analogs biosynthesized by manipulation of the C-1027 gene pathway.
REFERENCES:
patent: 5527805 (1996-06-01), Smith et al.
patent: 6297284 (2001-10-01), Kerwin et al.
Xie, Y., et al. (1997) Anti-Cancer Drug Design 12, 169-179.
Liu, W., et al. (2002) Science 297, 1170-1173.
Thorson, J.S., et al. (1999) Bioorganic Chemistry 27, 172-188.
Liu, W. et al. (2000) Antimicrobial Agents and Chemotherapy 44, 382-392.
Görth, F.C., et al. (2000) Eur. J. Org. Chem., 2605-2611.
Thorson, J.S., et al. (2000) Current Pharmaceutical Design 6, 1841-1879.
Tanaka, T., et al. (2001) J Mol Biol 309, 267-283.
Kuo, H.M., et al. (2002) Biochemistry 41, 897-905.
Lopez-Larraza, D.M., et al. (2001) Chem Res Toxicol 14, 528-535.
Jones, G.B., et al. (2000) Org Lett 2, 811-813.
Tuntiwechapikul, W., et al. (2002) Biochemistry 41, 5283-5290.
Jiang, B., Li, D.D., et al. (1995) Biochem Biophys Res Commun 208, 238-244.
Xu, Y.J., et al. (1994) Biochemistry 33, 5947-5954.
Okuno, Y., et al. (1994) J. Med Chem 37, 2266-2273.
Xu, Y.J., et al. (1997) Biochemistry 36, 14975-14984.
Cane, D.E., et al. (1998) Science 282, 63.
Du, L., et al. (2001) Curr. Opin. Drug Discov. Dev. 4, 215.
Staunton, J., et al. (2001) Nat. Prod. Rep. 18, 380.
Shen, B. (2000) Top. Curr. Chem. 209, 1.
Smith, A.L., et al. (1996) J. Med. Chem. 39, 2103-2117.
Sievers, E.L. et al. (2001) Curr. Opin. Oncol. 13, 522-527.
Chen, Y., et al. (2002) Acta Crystallogr D. Biol Crystallogr 58, 173-175.
Mitchell et al, Future of Monoclonal Antibodies in the Treatment of Hematologic Malignancies, Cancer Control, Mar./Apr. 2002, pp. 152-166, vol. 9, No. 2.
Katrin et al, Targeted Therapy of Experimental Renal Cell Carcinoma with a Novel Conjugate of Monoclonal Antibody 138H11 and Calicheamicin l11, Cancer Research 60, 6089-6095, Nov. 1, 2000.
Reff et al, Future Approaches for Treating Hematologic Disease, Current Pharmaceutical Biotechnology, vol. 2, No. 4, Dec. 2001, pp. 369-382(14).
Liang et al, Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma, World J Gastroenterol Aug. 7, 2005;11.
Marshall et al, Calicheamicin Derivatives Conjugated toMonoclonal Antibodies: Determination of LoadingValues and Distributions by Infrared and UVMatrix-Assisted Laser Desor, Analytical Chemistry, vol. 69, No. 14, Jul. 1997.
http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/M/Monoclonals. html.
Nicolaou et al, Chemistry and biology of natural and designed enediynes, Proc Natl Acad Sci U S A. Jul. 1, 1993;90(13):5881-8.
Henry, Celia M., Drug Delivery, CN&E, vol. 8, No. 34 pp. 39-47, Aug. 26, 2002.
Hinman, Lois M. et al.; “Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: A Novel and Potent Family of Antitumor Antibiotics” Jul. 15, 1993; Cancer Res. 53, 3336-3342.
Zhen, Li J. et al.; “Biodistribution of monoclonal antibody and Fab fragment and antitumor effect of their conjugates on hepatoma xenografts”, Oct. 16, 1994; Inst. Of Med. Bio., Beijing;16(5):328-33.
Zhou, CS et al., “A monoclonal antibody directed against an enediyne antitumor antibiotic and its preliminary application,” 1997; Inst. Of Med. Bio., Chinese Acad. Of Med Sc; 32(1):28-32.
Liu, XY et al., “Antitumor effect of lidamycin-containing monocional antibody immunoconjugate with downsized-molecule” 2001: Inst. Of Med. Bio., CAMS, Beijing: 23(6):563-7; Dec. 23, 2001.
Borders, Donald B. et al., eds. “Enediyne Antibiotics as Antitumor Agents.” (NY, Basel, Hong Kong:Marcel Dekker, Inc.); 1995, no mth available.
H. Maeda et al., eds. “Neocarzinostatin—The Past, Present, and Future of an Anticancer Drug.” (Springer-Verlag Tokyo); 1997.
E.L. Sievers et al., “Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate;” Blood 93: Jun. 11, 1999, pp. 3678-3684.
Brukner (2000) “Curr. Opinion Oncologic, Endocrine & Met. Invest. Drugs” 2:344, no mth available.
Liu Wen
Shen Ben
Godfrey & Kahn S.C.
Peselev Elli
Srivastava Sonali S.
Wisconsin Alumni Research Foundation (WARF)
LandOfFree
Biosynthesis of enediyne compounds by manipulation of C-1027... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biosynthesis of enediyne compounds by manipulation of C-1027..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biosynthesis of enediyne compounds by manipulation of C-1027... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3562119